AstraZeneca : 2023 Sustainability Highlights presentation

2023 Sustainability Highlights

Conference call for investors and analysts

March 2024

Forward-looking statements

In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter 'the Group') provides the following cautionary statement: this document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond the Group's control, include, among other things: the risk of failure or delay in delivery of pipeline or launch of new medicines; the risk of failure to meet regulatory or ethical requirements for medicine development or approval; the risk of failure to obtain, defend and enforce effective IP protection and IP challenges by third parties; the impact of competitive pressures including expiry or loss of IP rights, and generic competition; the impact of price controls and reductions; the impact of economic, regulatory and political pressures; the impact of uncertainty and volatility in relation to the UK's exit from the EU; the risk of failures or delays in the quality or execution of the Group's commercial strategies; the risk of failure to maintain supply of compliant, quality medicines; the risk of illegal trade in the Group's medicines; the impact of reliance on third-party goods and services; the risk of failure in information technology, data protection or cybercrime; the risk of failure of critical processes; any expected gains from productivity initiatives are uncertain; the risk of failure to attract, develop, engage and retain a diverse, talented and capable workforce; the risk of failure to adhere to applicable laws, rules and regulations; the risk of the safety and efficacy of marketed medicines being questioned; the risk of adverse outcome of litigation and/or governmental investigations; the risk of failure to adhere to increasingly stringent anti-bribery and anti-corruption legislation; the risk of failure to achieve strategic plans or meet targets or expectations; the risk of failure in financial control or the occurrence of fraud; the risk of unexpected deterioration in the Group's financial position; and the impact that the COVID-19 global pandemic may have or continue to have on these risks, on the Group's ability to continue to mitigate these risks, and on the Group's operations, financial results or financial condition. Nothing in this document, or any related presentation/webcast, should be construed as a profit forecast.

2	March 2024

Sustainability

at AstraZeneca

Pam Cheng

E X E C U T I V E	V I C E P R E S I D E N T, G L O B A L
O P E R AT I O N S , I N F O R M AT I O N T E C H N O L O G Y
A N D C H I E F	S U S TA I N A B I L I T Y O F F I C E R

Sustainability Governance at AstraZeneca

Board of Directors - Delegated Committees
	Board Audit Committee		Sustainability Committee			Remuneration Committee
Philip Broadley		Nazneen Rahman		Sheri McCoy
Senior Independent Non-Executive Director of the Board,	Non-Executive Director of the Board,		Non-Executive Director of the Board,
Chair of the Audit Committee		Chair of the Sustainability Committee		Chair of the Remuneration Committee
Sheri McCoy		Sheri McCoy			Nazneen Rahman
Non-Executive Director of the Board		Non-Executive Director of the Board		Non-Executive Director of the Board
Deborah DiSanzo		Marcus Wallenberg		Philip Broadley
Non-Executive Director of the Board		Non-Executive Director of the Board		Senior Independent Non-Executive Director of the Board
Anna Manz		Andreas Rummelt
Non-Executive Director of the Board		Non-Executive Director of the Board
Senior Executive Team (SET)		Pam Cheng			Jeff Pott
Pascal Soriot
	Executive Vice President, Global Operations,		Chief Human Resources Officer, Chief Compliance Officer
Executive Director and Chief Executive Officer
	Information Technology and Chief Sustainability Officer	and General Counsel
Sustainability Steering Committee
Sustainability	Compliance	Procurement	Communications	Legal	Finance	Human Resources	Supply Chain	Health Equity

March 2024

SET = Senior Executive Team.

2023 Sustainability highlights

Progress on our overall strategy includes:

15

public and private sector organisations convened by AstraZeneca CEO through the SMI to accelerate transition to net- zero health systems

87%

Access to Healthcare Environmental Protection Ethics and Transparency

127,384	67.6%	50.1%
healthcare workers and others trained1	reduction in Scope 1 and Scope 2	senior middle management roles
(cumulative)	greenhouse gas emissions	held by women
By 2025: 170,000	By 2026: 98% from 2015 base year	By 2025: reach gender equality in
		management positions
>66.4m	19.5%	11 countries

of employee survey respondents say that they understand their contributions to our sustainability priorities

25/27

of sustainability targets in Sustainability Data Annex are "on plan"

people reached through Access to Healthcare programmes (cumulative)1

By 2025: 50m

>13.6m

people reached through our patient assistance programmes (cumulative)

reduction in our water use	with supplier diversity programmes
By 2025: 20% below 2015 baseline	By 2025: 10 new countries outside of the US

13.2%	83%
reduction in our waste	of employee survey respondents feel we
By 2025: 10% below 2015 baseline	have a "speak up" culture

5 1. From our philanthropic programmes including; Healthy Heart Africa and Young Health Programme.

March 2024

CEO = Chief Executive Officer; SMI = Sustainable Markets Initiative.

Access to Healthcare

Securing a future of access to affordable, sustainable, and innovative healthcare

Our ambition:

to promote prevention, increase

access to life-saving treatments

and strengthen global healthcare

resilience and sustainability

Our focus:

Progress in 2023

66.4m People reached1

127.3k		Healthcare workers
	trained1

TARGETS:

50m

by2025

170k

by2025

Strategy update

Broadening beyond

philanthropic programmes for new

HEALTH EQUITY strategy

COMPREHENSIVE STRATEGY

from science to delivery of care

Innovating

Partnering

Transforming

Access to Healthcare

programmes include:

HealthyLung

YoungHealthProgramme
Metric"ON PLAN"	MetricACHIEVED

Implementing

END-to-END SOLUTIONS

across entire value chain

Further detail on Health Equity

strategy later in 2024

6	March 2024

1. From our philanthropic programmes including; Healthy Heart Africa and Young Health Programme.

Access to Healthcare

Partnering to drive focused interventions and policy change

Partnership for Health System Sustainability and Resilience (PHSSR)

Access in Action: PHSSR impact case studies

Committed to collaborating across SECTORS and BORDERS

Building more

SUSTAINABLE and

RESILIENT health systems

Co-founded by:

European Union

Acting Early on NCDs

launched at European Parliament

Focus:

• Data and analytics
• Prevention and early intervention
• Innovative technologies and solutions

Japan

Digital solutions

developed a digital platform for collecting and sharing medical information

Platform supporting:

• Guideline-basedtherapeutic decisions
• Detection of patients at early stages of their diseases

Brazil

Primary and community-based care

identifying financial mechanisms to:

• Strengthen primary care
• Improve community- based disease management services

Improving global health by building more sustainable and resilient health systems

7	March 2024

PHSSR = Partnership for Health System Sustainability and Resilience; NCD = non-communicable disease.

Access to Healthcare - Clinical Trial Diversity

Committed to designing clinical trials with equity at the forefront

Focused on:

PATIENT CENTRICITY

DATA DRIVEN approach

SCIENCE-LEDexecution

Progress in 2023

PUBLICATION

including retrospective analysis of 246 clinical trials in the US

Launch of internal

CTD DASHBOARD

MONITORING CTD in the US

real-time tracking of for all recruiting Phase III trials1

Committed to:

Designing

INCLUSIVE TRIALS

Optimising

RECRUITMENT and

RETENTION of UREs

Improving

TRIAL DIVERSITY

8 1. Current real-time tracking of race and ethnicity for all recruiting Phase III trials sponsored by AstraZeneca with plans to expand to include age and sex in 2024.	March 2024
CTD = clinical trial diversity; FDA = US Food and Drug Administration; URE = under-represented ethnicities.

Environmental Protection

Driving bold decarbonisation through Ambition Zero Carbon

Scope 1

Scope 2

Scope 1 & 2

TARGETS:

Total Revenue vs. Scope 1 & 2 emissions

Scope 3	Scope 3
	TARGETS:

68%

35%

103%

95%

Reduce Scope 1 & 2 emissions vs. 2015

Transition to electric vehicles

Increase energy

productivity vs. 2015

Increase

renewable electricity consumption vs. 2015

98%

by2026

100%

by20251

200%

by2025

100%

from2025

Revenue($m)	$50,000		700,000	Emissions2 (tCO2e)
$20,000	300,000
	$45,000	600,000
	$40,000		500,000
	$35,000
	$30,000
	400,000
Total	$25,000			&1Scope
$15,000		200,000
	$10,000
	100,000
	$5,000
	$-		-

Revenue ($m)

Scope 1 & 2 (tCO2e)

SBTi Default Pathway (tCO2e)

60%		Of suppliers with		20251
	science-based targets
		Launch next-generation			Byendof
				2025
		near-zero GWP inhaler

Scope 3: strategic emissions approach

Metric"ON PLAN"

9 1. By 2025, 95% of our suppliers by spend covering purchased goods and services and capital goods, and 50% of our suppliers by spend covering upstream transportation and distribution and business travel, will have SBTs.	March 2024
tCO2e = tonnes of carbon dioxide equivalent; SBTi = Science Based Targets Initiative; GWP = Global Warming Potential.

Biodiversity at AstraZeneca

Integrating a circular economy approach across our value chain

Circular economy

			Incorporate principles of the
			circulate economy
			Minimise
Develop
suitable			amount of
metrics			materials
				Increase reused
Maximise
		or recycled
waste recycled
		content
			Regenerate
			nature

Biodiversity

bringing nature more prominently into decision-making

By END of 2024:

Develop framework of biodiversity with

RISKS and DEPENDENCIES

Developing

TARGETS and METRICS

according to SBTN

Supporting:

AZ Forest

maximising the co-benefits of reforestation

					TARGETS:
20m		Trees planted and			200m
	maintained since 2020			by2030

Reforestation

designed to:

• Foster biodiversity
• Support sustainable livelihoods
• Build local climate resilience

Metric"ON PLAN"

10	March 2024

SBTN = Science Based Targets Network.